Journal Watch · Frontiers in Immunology · 2026

Roles of sex and SP-A genetic variants in modulating multiorgan injuries post viral infection.

These findings highlight the importance of host genetic variation in innate immunity and suggest that SP-A variants, together with sex-specific considerations, may inform risk stratification and therapeutic strategies for COVID-19 and related viral diseases.

Williams ZM, Jacob IB, Lawal AO et al.Frontiers in Immunology4 min readPharma relevance 40/100

DOI: 10.3389/fimmu.2026.1866913PMID: 42698575Study type: preclinical (animal / model) study

TL;DR

These findings highlight the importance of host genetic variation in innate immunity and suggest that SP-A variants, together with sex-specific considerations, may inform risk stratification and therapeutic strategies for COVID-19 and related viral diseases.

Key findings

  • In the kidney, 1A<sup>0</sup> and 6A<sup>4</sup> variants showed the greatest protection, again with stronger effects in females.
  • In contrast, intestinal injury was attenuated by SP-A variants independent of sex.
  • Across tissues, SP-A deficiency was associated with increased viral burden and inflammation.
  • Mechanistically, SP-A variants differentially bound SARS-CoV-2 S protein and RBD, with the 1A<sup>0</sup> variant demonstrating the stronger binding and greater inhibition of viral infectivity compared to 6A<sup>2</sup> variant <i>in vitro</i>.<h4>Conclusions</h4>Human SP-A genetic variants and biological sex interact to modulate SARS-CoV-2-induced multi-organ injury in a tissue-specific manner.
  • These findings highlight the importance of host genetic variation in innate immunity and suggest that SP-A variants, together with sex-specific considerations, may inform risk stratification and therapeutic strategies for COVID-19 and related viral diseases.

What they did

Male and female mice were intranasally infected with SARS-CoV-2 (Delta variant) and assessed on day 6 post-infection. Histopathological analyses were performed to evaluate lung, kidney, and intestinal injury. In parallel, <i>in vitro</i> assays assessed SP-A variant binding to viral spike (S) protein and receptor-binding domain (RBD), as well as effects on viral infectivity in lung epithelial cells.<h4>Results</h4>SP-A variants significantly attenuated SARS-CoV-2-induced organ injury compared to KO mice, with SP-A variant and organ-specific effects. In the lung, injury severity followed the order 6A<sup>2</sup> > 1A<sup>0</sup> > K18 > 1A<sup>3</sup> > 6A<sup>4</sup>, with female mice, particularly those expressing 1A<sup>3</sup> and 6A<sup>4</sup>, exhibiting markedly reduced ALI compared to males.

Full abstract (original)

Background: <h4>Background</h4>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), and multi-organ dysfunction (MOD). Human surfactant protein A (SP-A), a key component of innate immunity, exhibits genetic polymorphisms that may influence host responses to viral infection. Human patient studies have shown that biological sex has been associated with differences in COVID-19 severity. However, the combined effects of SP-A variants and sex on SARS-CoV-2-induced organ injury remain poorly understood.<h4>Methods</h4>We utilized double-humanized transgenic mice expressing human ACE2 and individual human SP-A variants (6A<sup>2</sup>, 6A<sup>4</sup>, 1A<sup>0</sup>, 1A<sup>3</sup>), alongside SP-A knockout (KO) and wild-type (K18) controls.

What they did: Male and female mice were intranasally infected with SARS-CoV-2 (Delta variant) and assessed on day 6 post-infection. Histopathological analyses were performed to evaluate lung, kidney, and intestinal injury. In parallel, <i>in vitro</i> assays assessed SP-A variant binding to viral spike (S) protein and receptor-binding domain (RBD), as well as effects on viral infectivity in lung epithelial cells.<h4>Results</h4>SP-A variants significantly attenuated SARS-CoV-2-induced organ injury compared to KO mice, with SP-A variant and organ-specific effects. In the lung, injury severity followed the order 6A<sup>2</sup> > 1A<sup>0</sup> > K18 > 1A<sup>3</sup> > 6A<sup>4</sup>, with female mice, particularly those expressing 1A<sup>3</sup> and 6A<sup>4</sup>, exhibiting markedly reduced ALI compared to males.

Results & conclusions: In the kidney, 1A<sup>0</sup> and 6A<sup>4</sup> variants showed the greatest protection, again with stronger effects in females. In contrast, intestinal injury was attenuated by SP-A variants independent of sex. Across tissues, SP-A deficiency was associated with increased viral burden and inflammation. Mechanistically, SP-A variants differentially bound SARS-CoV-2 S protein and RBD, with the 1A<sup>0</sup> variant demonstrating the stronger binding and greater inhibition of viral infectivity compared to 6A<sup>2</sup> variant <i>in vitro</i>.<h4>Conclusions</h4>Human SP-A genetic variants and biological sex interact to modulate SARS-CoV-2-induced multi-organ injury in a tissue-specific manner. These findings highlight the importance of host genetic variation in innate immunity and suggest that SP-A variants, together with sex-specific considerations, may inform risk stratification and therapeutic strategies for COVID-19 and related viral diseases.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1866913 · PubMed 42698575.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

These findings highlight the importance of host genetic variation in innate immunity and suggest that SP-A variants, together with sex-specific considerations, may inform risk stratification and therapeutic strategies for COVID-19 and related viral diseases.

What type of study is this?

It is a preclinical (animal / model) study, published in Frontiers in Immunology in 2026. Male and female mice were intranasally infected with SARS-CoV-2 (Delta variant) and assessed on day 6 post-infection.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1866913. PubMed ID: 42698575. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Williams ZM, Jacob IB, Lawal AO et al.. Roles of sex and SP-A genetic variants in modulating multiorgan injuries post viral infection.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1866913.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/roles-of-sex-and-sp-a-genetic-variants-in-modulating-multiorgan-injuries-866913/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides